Abstract
Inflammation may be one of the independent risk factors contributing to many neurological diseases. Moreover, there is an emerging body of data indicating that statins may have neuroprotective action. Recent studies suggest that CD40-CD40 ligand (CD40L) system is proven to be an important mediator of several auto-immune and chronic inflammation diseases. To address whether lovastatin produces neuroprotection as a potential novel anti-inflammatory pathway through the inhibition of CD40 expression, we examined the possible effects of lovastatin on expression of CD40, apoptosis, level of nitric oxide (NO) and nitric oxide synthase (NOS) activity induced by tumor necrosis factor α (TNF-α) in the cerebral vascular endothelial cells (CVECs) involved in cerebrovascular diseases. Preincubation with lovastatin (10-7, 10-6 and 10-5 mol/l) for 24 hours (h) protected CVECs from TNF-α-induced decrease of cellular viability. Further, lovastatin inhibited the TNF-α-induced increases of NO level, NOS activity, apoptotic cells and CD40 expression in a dosedependent manner, and anti-CD40 antibody also inhibited the cellular apoptosis induced by TNF-α. In conclusion, our data provide evidence to support a direct pro-inflammatory effect of CD40-CD40L signaling pathway in CVECs, and lovastatin possesses an anti-inflammatory effect independent of its lipid-lowering action involved in the cerebrovascular diseases.
Keywords: Lovastatin, TNF-α, CD40, apoptosis, NO, NOS, cerebral vascular endothelial cell
Current Neurovascular Research
Title: Lovastatin Reduces Apoptosis and Downregulates the CD40 Expression Induced by TNF-α in Cerebral Vascular Endothelial Cells
Volume: 3 Issue: 1
Author(s): Rong Lin, Juntian Liu, Ning Peng, Weijie Gan, Weirong Wang, Chunjie Han and Cunjing Ding
Affiliation:
Keywords: Lovastatin, TNF-α, CD40, apoptosis, NO, NOS, cerebral vascular endothelial cell
Abstract: Inflammation may be one of the independent risk factors contributing to many neurological diseases. Moreover, there is an emerging body of data indicating that statins may have neuroprotective action. Recent studies suggest that CD40-CD40 ligand (CD40L) system is proven to be an important mediator of several auto-immune and chronic inflammation diseases. To address whether lovastatin produces neuroprotection as a potential novel anti-inflammatory pathway through the inhibition of CD40 expression, we examined the possible effects of lovastatin on expression of CD40, apoptosis, level of nitric oxide (NO) and nitric oxide synthase (NOS) activity induced by tumor necrosis factor α (TNF-α) in the cerebral vascular endothelial cells (CVECs) involved in cerebrovascular diseases. Preincubation with lovastatin (10-7, 10-6 and 10-5 mol/l) for 24 hours (h) protected CVECs from TNF-α-induced decrease of cellular viability. Further, lovastatin inhibited the TNF-α-induced increases of NO level, NOS activity, apoptotic cells and CD40 expression in a dosedependent manner, and anti-CD40 antibody also inhibited the cellular apoptosis induced by TNF-α. In conclusion, our data provide evidence to support a direct pro-inflammatory effect of CD40-CD40L signaling pathway in CVECs, and lovastatin possesses an anti-inflammatory effect independent of its lipid-lowering action involved in the cerebrovascular diseases.
Export Options
About this article
Cite this article as:
Lin Rong, Liu Juntian, Peng Ning, Gan Weijie, Wang Weirong, Han Chunjie and Ding Cunjing, Lovastatin Reduces Apoptosis and Downregulates the CD40 Expression Induced by TNF-α in Cerebral Vascular Endothelial Cells, Current Neurovascular Research 2006; 3 (1) . https://dx.doi.org/10.2174/156720206775541796
DOI https://dx.doi.org/10.2174/156720206775541796 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D Deficiency and Oxidative Stress in Type 2 Diabetic Population of India
Cardiovascular & Hematological Agents in Medicinal Chemistry Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design Editorial [Hot topic: Antithrombotic Therapy in Cardiovascular and Haematological Diseases: New Perspectives (Executive Editors: Sergio Siragusa, Giuseppe Barbaro and Giovanni Fazio)]
Current Pharmaceutical Design Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Renal Ischemia: How Commonly Does it Cause Renal Failure?
Current Hypertension Reviews Structural MRI Biomarkers of Mild Cognitive Impairment from Young Elders to Centenarians
Current Alzheimer Research The Genetics of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews 3D Cell and Scaffold Patterning Strategies in Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Which is the Optimal Antihypertensive Combination in Different Diseases, a Renin- Angiotensin-aldosterone System Inhibitor with a Diuretic or with a Calcium Channel Blocker?
Current Pharmaceutical Design A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Blood Pressure Control and Antihypertensive Treatment
Current Vascular Pharmacology Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets The Autocrine/Paracrine Loop After Myocardial Stretch: Mineralocorticoid Receptor Activation
Current Cardiology Reviews Contribution of Ultrasonography of Hands and Wrists in Early Rheumatoid Arthritis
Current Rheumatology Reviews Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine